Dosage guide · 20 mg vial

Vesugen Dosage Protocol

Lys-Glu-Asp (KED) · short vascular bioregulator peptide

The reference protocol uses a once-daily subcutaneous amount: 500 mcg in week 1, 1 mg in week 2, 1.5 mg in week 3, then 1.5–2 mg daily. With 3 mL in a 20 mg vial, concentration is 6.67 mg/mL and 500 mcg measures 7.5 units (0.075 mL) on a U-100 syringe.

How oftenOnce daily

Starting dose500 mcg

Start = units7.5 units

Mix3 mL BAC water

Reviewed 25 Oct 2026 · Education only, not medical advice

Vesugen 20 mg vial

Not currently stocked by Peak Peptides Australia

No product photo — this strength isn't stocked by Peak

Dosage chart How to mix Supplies Calculator About Vesugen References

01 · DOSAGE CHART

Vesugen dosage chart

Gradual daily approach · 20 mg vial + 3 mL BAC water

BAC water added

Concentration6.67 mg/mL

1 unit (U-100)66.7 mcg= 0.01 mL

How oftenOnce dailySubcutaneous injection

3 mL is the reference site's Vesugen mix, making 6.67 mg/mL, so 500 mcg is 7.5 U-100 units.

Vesugen dosage chart for a 20 mg vial mixed with 3 mL of bacteriostatic water
Week	Daily dose	Syringe units
Week 1Start	500 mcg	7.5 units0.075 mL
Week 2	1 mg	15 units0.15 mL
Week 3	1.5 mg	22.5 units0.225 mL
Weeks 4–8+Maintenance	1.5–2 mg	22.5–30 units0.225–0.3 mL

Once daily · any consistent time · subcutaneous injection

The attributed chart increases by 500 mcg at each weekly step through week 3.

Its final row is 1.5–2 mg once daily from week 4; it does not give criteria for choosing within that range.

The source provides 8-, 12- and 16-week supply estimates.

Reference-site educational amounts — Vesugen has no clinically established human dose and is not presented as a TGA-approved medicine. Education only, not medical advice. Dose amounts adapted from Vesugen Lys-Glu-Asp 20 mg vial dosage protocol (PeptideDosages.com); units are recalculated for the vial and mix selected above.

02 · HOW TO MIX

Mixing a 20 mg vial with 3 mL of BAC water

Using a 1 mL (100-unit) insulin syringe, 3 full draws of bacteriostatic water gives 6.67 mg/mL.

1
Add the water slowly
Wipe both rubber stoppers with an alcohol swab and let them dry. Draw 3 mL of bacteriostatic water and let it run slowly down the inside of the vial wall — not straight onto the powder.
2
Swirl gently
Swirl or roll the vial gently until the powder has dissolved. Give it a few minutes to settle if needed.
3
Don't shake it
Shaking can damage the peptide and cause foaming. Gentle swirling only.
4
Check it's fully clear
Only use it once it is fully clear with no particles. Label the vial with the date and 6.67 mg/mL, then store it in the fridge at 2–8 °C.

Full illustrated reconstitution guide

03 · SUPPLIES NEEDED

What you'll need

Counts follow the dosage chart above at the highest amount in each step, using a 20 mg vial mixed with 3 mL.

Length of protocol

5Vesugen 20 mg vials91 mg needed in total

611 mL insulin syringesU-100, 27–31G · one per draw + one per vial mixed

2BAC water 10 mL bottles15 mL used for mixing

122Alcohol swabsSkin + stopper, every time

Plus an approved sharps container. Syringes and swabs are sold by Australian pharmacies — Peak Peptides and Pure Performance supply the bacteriostatic water.

Peak Peptides Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPeak Peptides Australia

Pure Performance Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPure Performance Australia

04 · CALCULATOR

Check a different amount

Enter your vial, water and dose to see the matching syringe units.

Concentration Calculator

Labelled Vial Amount (mg)

Verified Final Liquid Volume3 mL

Amount to Evaluate (not a recommendation)

mcg

Concentration

6.67 mg/mL

(6667 mcg/mL)

Calculated Liquid Volume

0.075 mL

Equivalent U-100 volume scale position

7.5markings (not biological IU)

Illustration of a U-100 volume scale, not preparation or injection guidance

05 · PROTOCOL DETAILS

About Vesugen

Protocol overview

Starting dose: 500 mcg once daily in week 1
How it increases: 1 mg in week 2, 1.5 mg in week 3, then 1.5–2 mg daily
Frequency: Once daily
When to take it: Any consistent time; the attributed protocol gives no preferred time
Reference duration: Supply estimates are provided for 8, 12 and 16 weeks
Common mix: 3 mL bacteriostatic water → 6.67 mg/mL

Storage

Before mixing: The attributed protocol says to keep the lyophilised vial at −20 °C, dry and protected from light.
After mixing: The attributed protocol says 2–8 °C, protected from light; no product-specific in-use stability period was found.
Never: Avoid repeated freeze-thaw cycles or use if the solution is cloudy, discoloured or has particles.

How it works

Vesugen is the short synthetic tripeptide Lys-Glu-Asp, also called KED. It is one of the Khavinson-family peptide bioregulators discussed in laboratory research.

In a 2014 report, KED/Vesugen was examined in cultured vascular endothelial cells and with molecular docking around the MKI67 promoter. These findings are laboratory observations, not proof of a clinical vascular benefit.

A 2016 in-vitro paper reported changes in endothelin-1, connexin and sirtuin-1 expression in endothelial models. The mechanism and relevance to people remain uncertain.

Illustrated mechanism explainer

What the research shows

The 2014 Vesugen report used tissue-specific cell cultures from young and old animals and dissociated vascular endothelial cell cultures; it reported Ki-67-related findings and molecular-docking results.
The 2016 KED paper studied normal, atherosclerotic and restenotic endothelium in vitro, so it does not establish a clinical outcome or an injectable human dose.
A ClinicalTrials.gov search for “Vesugen” returned 0 studies when checked on 25 October 2026.
No official TGA or FDA product label defining a Vesugen dose was identified in this review. The TGA states that therapeutic goods absent from the ARTG have not been assessed by it for safety, quality or effectiveness.

Reported side effects

No controlled human safety dataset or dose-related adverse-event rate was located for Vesugen, so short- and long-term effects are unknown.
For injectable preparations, the DailyMed bacteriostatic-water label lists reactions that may arise from the solution, added drug or technique, including local tenderness, abscess, infection and tissue necrosis.
Bacteriostatic water contains benzyl alcohol and its label says it must not be used in neonates.

Important notes

Vesugen has no clinically established human dose and is not presented here as a TGA-approved medicine.
The amounts above are copied from an educational reference protocol, not from an approved product label or a human dose-escalation study.
WADA does not name Vesugen in the 2026 List, but S0 prohibits at all times pharmacological substances with no current approval by any governmental health authority; competing athletes should confirm status with their anti-doping organisation.
A research-supply label is not proof of identity, purity, sterility or concentration.
Never use a mixed vial that is cloudy or has particles in it.

Injection basics

Use a new sterile 1 mL (100-unit) U-100 insulin syringe, 27–31G, every time — never reuse or share.
Wipe the vial stopper and the skin with an alcohol swab and let both dry first.
Inject under the skin (subcutaneously) of the abdomen, thigh or upper arm, and rotate sites.
Put used syringes straight into an approved sharps container — the NDSS lists Australian disposal options.

Guidance: World Health Organization · National Diabetes Services Scheme (NDSS)

06 · QUICK ANSWERS